Enclomiphene Citrate vs Testosterone Enanthate: Head-to-Head Efficacy

How These Two Drugs Work Differently

Enclomiphene citrate and testosterone enanthate correct low testosterone through opposite pharmacologic strategies, and that distinction shapes every downstream clinical outcome.

Enclomiphene is the trans-isomer of clomiphene citrate. It acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary, blocking negative feedback from estradiol. This disinhibition raises gonadotropin-releasing hormone (GnRH) pulse frequency, which in turn increases luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion 1. The testes then produce more testosterone endogenously. Because FSH remains elevated, Sertoli cell function and spermatogenesis continue uninterrupted.

Testosterone enanthate takes the opposite approach. It delivers exogenous testosterone directly into circulation via an intramuscular depot injection, typically dosed at 100 to 200 mg every one to two weeks 2. Supraphysiologic peaks followed by troughs are common with biweekly dosing. The exogenous testosterone suppresses GnRH, LH, and FSH through negative feedback, which is why testicular volume decreases and sperm production falls, often to azoospermic levels, within 3 to 6 months of initiating therapy 3.

This mechanistic divide is not academic. It determines which patients can use each drug without sacrificing reproductive potential.

Testosterone Restoration: What the Data Show

No large, randomized, double-blind trial has directly compared enclomiphene citrate to testosterone enanthate in the same patient population. The evidence base relies on cross-trial comparison, which carries inherent limitations.

Kim et al. (2016) studied enclomiphene in men with secondary hypogonadism (baseline total testosterone <250 ng/dL) over 12 weeks. Mean total testosterone rose from approximately 228 ng/dL to 445 ng/dL, a 95% increase. LH increased from 3.1 to 7.7 mIU/mL, confirming HPG axis stimulation. Sperm concentration remained stable or improved 1.

The Testosterone Trials (TTrials), published in the New England Journal of Medicine, enrolled 790 men aged 65 and older with total testosterone <275 ng/dL. Participants received testosterone gel (not enanthate specifically, though enanthate produces comparable steady-state levels at equivalent doses). After 12 months, the testosterone group achieved mean levels of approximately 565 ng/dL versus 232 ng/dL in the placebo arm. Sexual activity scores improved by 0.58 points (vs. 0.16 for placebo), and the 6-minute walking distance increased by 6.1 meters more than placebo 2.

These numbers reveal a pattern. Exogenous testosterone achieves higher absolute serum levels more reliably. Enclomiphene produces meaningful increases that normalize testosterone in many men, though the ceiling is lower because it depends on existing testicular reserve.

A phase II trial by Wiehle et al. (2014) tested enclomiphene at 12.5 mg and 25 mg daily against topical testosterone gel 1%. At 12 weeks, the 25 mg enclomiphene arm achieved mean total testosterone of 604 ng/dL, statistically non-inferior to the gel arm. Sperm concentrations remained above baseline only in the enclomiphene groups 4.

Dr. Ronald Swerdloff, an endocrinologist at Harbor-UCLA Medical Center, has noted: "The ideal testosterone therapy would restore physiologic levels while maintaining the hypothalamic-pituitary-gonadal axis. Enclomiphene offers that possibility for a subset of patients with secondary hypogonadism" 5.

Fertility Preservation: The Defining Advantage of Enclomiphene

For men who want children now or may want them later, enclomiphene holds a clear pharmacologic advantage over testosterone enanthate.

Exogenous testosterone acts as a male contraceptive. The Endocrine Society's 2018 Clinical Practice Guideline states: "Testosterone therapy should not be initiated in men planning fertility in the near term, as exogenous testosterone suppresses spermatogenesis" 6. Studies estimate that 65% of men on TRT become azoospermic within 6 months, and while recovery occurs in most men after discontinuation, it can take 6 to 24 months, and some men never fully recover baseline sperm counts 3.

Enclomiphene, by contrast, raises FSH alongside testosterone. Kim et al. documented that mean sperm concentrations were maintained at 37.2 million/mL after 12 weeks of treatment, compared to a baseline of 35.8 million/mL 1. Several urologists now prescribe enclomiphene (or standard clomiphene citrate) off-label as first-line therapy for hypogonadal men of reproductive age.

This is not a subtle distinction. A 32-year-old man with secondary hypogonadism and a total testosterone of 220 ng/dL who starts testosterone enanthate 150 mg weekly may feel better within weeks but could face years of delayed fertility if he discontinues. The same patient on enclomiphene 25 mg daily may achieve a total testosterone of 450 to 550 ng/dL while keeping his sperm count intact.

Symptom Relief and Quality of Life

Symptom improvement matters more to most patients than a number on a lab report. Here the comparison becomes less clear-cut.

The TTrials demonstrated statistically significant improvements in sexual desire, erectile function, and physical function with testosterone therapy at 12 months 2. The Psychosexual Daily Questionnaire sexual desire score rose by 0.58 in the testosterone group versus 0.16 with placebo (P<0.001). The Physical Function substudy showed a 6.1-meter improvement in 6-minute walking distance.

Enclomiphene data on patient-reported outcomes are thinner. Phase II trials focused primarily on hormonal and semen endpoints. Anecdotal clinical reports suggest that symptom improvement is real but sometimes less pronounced than what men experience with injectable testosterone, particularly at higher doses. One reason: testosterone enanthate can push levels to the upper normal range (700 to 900 ng/dL) or beyond, while enclomiphene typically plateaus at 400 to 600 ng/dL depending on residual Leydig cell capacity.

Men with primary hypogonadism (testicular failure, elevated LH/FSH at baseline) are poor candidates for enclomiphene. If the testes cannot respond to increased gonadotropin stimulation, the drug will not work. Testosterone enanthate bypasses this limitation entirely. The American Urological Association's 2018 guideline on testosterone deficiency identifies primary hypogonadism as an indication for exogenous testosterone rather than SERMs 7.

Side-Effect Profiles

Both therapies carry risks, but the risk categories differ.

Testosterone enanthate's well-documented adverse effects include erythrocytosis (hematocrit elevation above 54%, seen in 3 to 18% of patients depending on dose and monitoring interval), acne, testicular atrophy, gynecomastia from aromatization to estradiol, and suppression of the HPG axis 6. The FDA requires a class-wide warning about potential cardiovascular risk, though the TRAVERSE trial (2023, N=5,204) found no significant increase in major adverse cardiovascular events (MACE) over a mean follow-up of 33 months (hazard ratio 0.96, 95% CI 0.78 to 1.17) 8. Injection-site pain and the inconvenience of regular injections also factor into adherence.

Enclomiphene's side-effect profile is lighter in most respects. Visual disturbances (a known risk with racemic clomiphene) appear less common with the isolated trans-isomer, though post-marketing data are limited because the drug lacks FDA approval for this indication. Headache and hot flashes occur at rates of approximately 5 to 10% in clinical trials. Because enclomiphene raises estradiol along with testosterone (a natural consequence of increased aromatase substrate), some men report mild breast tenderness 4.

One risk unique to enclomiphene is overstimulation in men with already-normal gonadotropins. Prescribers should confirm that LH is not already elevated before initiating therapy, as a high baseline LH suggests primary testicular failure and makes HPG-axis stimulation futile.

Dosing, Monitoring, and Practical Considerations

Testosterone enanthate is typically initiated at 100 to 200 mg intramuscularly every 7 to 14 days. Some clinicians split doses into 50 to 80 mg twice weekly to reduce peak-trough fluctuations. Labs are drawn at trough (the day of or the day before the next injection) at 6 to 12 weeks, then every 6 to 12 months. The minimum monitoring panel includes total testosterone, free testosterone, hematocrit, PSA (in men over 40), and a lipid panel 6.

Enclomiphene is dosed at 12.5 to 25 mg orally once daily. Response is assessed at 4 to 6 weeks with total testosterone, LH, FSH, and estradiol. Men who fail to achieve total testosterone above 400 ng/dL at 25 mg daily are unlikely to benefit from dose escalation and should be counseled about alternative options including exogenous testosterone 1.

Convenience favors enclomiphene. A daily pill requires no needle disposal, no injection-site rotation, and no cold-chain storage. Testosterone enanthate, while inexpensive and widely available, requires either clinic visits for administration or patient self-injection training.

Cost differences are modest for the generic versions of each. Testosterone enanthate 200 mg/mL (5 mL vial) runs approximately $30 to $75 at retail pharmacies with a GoodRx coupon. Compounded enclomiphene capsules range from $30 to $90 per month, though prices vary by pharmacy. Neither is typically covered by insurance for this indication when prescribed off-label (enclomiphene) or without a confirmed diagnosis meeting payer criteria (testosterone enanthate) 9.

Who Should Choose Which Therapy

The decision between enclomiphene and testosterone enanthate is not simply about which drug produces a higher number. It is about matching pharmacology to patient goals.

Enclomiphene is best suited for men with secondary hypogonadism (low testosterone, low or inappropriately normal LH/FSH) who want to preserve fertility, prefer oral dosing, or want to avoid long-term HPG-axis suppression. Younger men in their 20s and 30s, men actively trying to conceive, and men with obesity-related hypogonadism (where hypothalamic suppression from excess estradiol is the primary driver) are strong candidates 10.

Testosterone enanthate remains the standard of care for primary hypogonadism (Klinefelter syndrome, bilateral orchiectomy, testicular damage from chemotherapy or radiation), for men who have completed their families, and for patients who have tried enclomiphene without adequate testosterone restoration. It also serves men who need reliable supraphysiologic dosing for specific clinical scenarios under medical supervision.

Dr. Mohit Khera, a urologist at Baylor College of Medicine, has stated: "Clomiphene and its isomers have a role as first-line therapy for younger hypogonadal men who wish to maintain fertility. But for patients with severe symptoms and primary testicular failure, injectable testosterone remains the most effective option" 7.

Some clinicians use a sequential approach: start with enclomiphene to assess HPG-axis responsiveness, then transition to testosterone enanthate if the response is insufficient after 8 to 12 weeks. This strategy preserves the option of endogenous recovery while establishing whether the patient truly needs exogenous replacement.

Combination Protocols and Emerging Evidence

A small but growing body of evidence explores combining low-dose testosterone with enclomiphene to achieve higher serum levels while partially preserving gonadotropin secretion. The rationale is straightforward: a low dose of exogenous testosterone (e.g., 50 to 80 mg weekly) may not fully suppress LH if paired with a SERM that counteracts estrogen-mediated negative feedback.

No randomized trial has validated this approach. Case series from men's health clinics report that the combination can maintain sperm counts above 10 million/mL (sufficient for natural conception in many cases) while achieving total testosterone levels of 600 to 800 ng/dL 10. These data are preliminary and should not be generalized.

The FDA declined to approve enclomiphene (under the brand name Androxal) in 2015, citing inadequate long-term safety data and concerns about the clinical meaningfulness of the primary endpoint (testosterone normalization without patient-reported outcome improvement). Since then, enclomiphene has been available through compounding pharmacies, and several pharmaceutical companies have expressed interest in revisiting the approval pathway with updated trial designs.

Ongoing research includes investigations into oral testosterone undecanoate (Jatenzo, FDA-approved in 2019) as a third option that provides exogenous testosterone orally, though it still suppresses the HPG axis 11. Nasal testosterone (Natesto) represents another delivery route with potentially less gonadotropin suppression than injectable forms, though the evidence on fertility preservation remains mixed.

For men weighing these options in 2026, the clinical decision still rests on two questions: does this patient need to preserve fertility, and can his testes respond to gonadotropin stimulation? The answers determine the therapy.